Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Sugammadex (Org 25969, modified gamma-cyclodextrin)].

Takahiro Suzuki1

  • 1Department of Anesthesiology, Surugadai Nihon University Hospital, Tokyo 101-8309.

Masui. the Japanese Journal of Anesthesiology
|July 22, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptome analysis reveals inadequate spermatogenesis and immediate radical immune reactions during organ culture in vitro spermatogenesis.

Biochemical and biophysical research communications·2020
Same author

Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease.

Digestive diseases (Basel, Switzerland)·2020
Same author

A Rare Case of Elongated Styloid Process Fracture.

The American journal of case reports·2020
Same author

[Novel Technology for Studying Insulin Secretion: Imaging and Quantitative Analysis by a Bioluminescence Method].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·2020
Same author

Functional annotation of human long noncoding RNAs via molecular phenotyping.

Genome research·2020
Same author

High-dose rocuronium-induced paralysis of the adductor pollicis muscle facilitates detection of the timing for tracheal intubation in elderly patients: a randomized double-blind study.

Journal of anesthesia·2020

Sugammadex effectively and rapidly reverses rocuronium-induced neuromuscular blockade. This selective agent offers a safe alternative to traditional reversal methods, with no observed recurarization or anticholinesterase side effects.

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Sugammadex is a modified gamma-cyclodextrin designed as a selective reversal agent.
  • Rocuronium is a steroidal neuromuscular blocking agent.
  • Sugammadex forms a 1:1 host-guest complex with rocuronium via encapsulation and electrostatic attraction.

Purpose of the Study:

  • To evaluate the efficacy and safety of sugammadex as a reversal agent for rocuronium-induced neuromuscular blockade.
  • To investigate the mechanism of action and pharmacokinetic profile of sugammadex.
  • To compare sugammadex with traditional reversal agents, such as anticholinesterases.

Main Methods:

  • Administration of sugammadex (8 mg x kg(-1)) intravenously during profound rocuronium-induced block.

Related Experiment Videos

  • Monitoring of neuromuscular function using train-of-four ratio of thenar muscle to ulnar nerve stimulation.
  • Assessment of reversal speed and duration.
  • Evaluation of potential interactions with anesthetics and cholinergic systems.
  • Observation for side effects, including recurarization.
  • Analysis of excretion pathways, particularly renal excretion.

    • Main Results:

    • Sugammadex rapidly reversed profound rocuronium-induced neuromuscular blockade, with the train-of-four ratio returning to 0.9 within 2 minutes.
    • The rapid reversal is attributed to the quick redistribution of free rocuronium from the neuromuscular junction to the plasma.
    • Reversal effects were not influenced by anesthetics and showed no interaction with cholinergic systems.
    • No undesired side effects associated with anticholinesterases were observed.
    • No recurarization was noted after sugammadex administration.
    • The sugammadex-rocuronium complex is primarily excreted via the kidneys, with complete reversal effects even in patients with renal failure.

    Conclusions:

    • Sugammadex is a highly effective and selective agent for the rapid reversal of rocuronium-induced neuromuscular blockade.
    • Sugammadex offers a favorable safety profile, avoiding the side effects associated with anticholinesterase reversal agents.
    • The drug's efficacy is maintained even in patients with renal impairment, highlighting its clinical utility.
    • Sugammadex represents a significant advancement in the management of neuromuscular blockade during anesthesia.